Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial (Q39396121)

11 September 2017

Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial (English)

1 reference

11 September 2017

1 reference

https://api.crossref.org/works/10.1016/S0197-2456(02)00263-5

23 December 2023

8

Steven A Kaplan

1 reference

11 September 2017

3

Leroy M Nyberg

1 reference

11 September 2017

2

John W Kusek

1 reference

11 September 2017

Gary Miller

6

1 reference

11 September 2017

Hebert Lepor

11

1 reference

11 September 2017

Oliver M. Bautista

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12689743

23 December 2023

John D. McConnell

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12689743

23 December 2023

Raymond P. Bain

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12689743

23 December 2023

E. David Crawford

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12689743

23 December 2023

Stephen A. Sihelnik

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12689743

23 December 2023

Michael K. Brawer

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12689743

23 December 2023

language of work or name

English

0 references

publication date

1 April 2003

1 reference

full work available at URL

11 September 2017

https://api.elsevier.com/content/article/PII:S0197245602002635?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0197-2456(02)00263-5

https://api.elsevier.com/content/article/PII:S0197245602002635?httpAccept=text/plain

23 December 2023

1 reference

https://api.crossref.org/works/10.1016/S0197-2456(02)00263-5

Contemporary Clinical Trials

23 December 2023

published in

1 reference

11 September 2017

24

1 reference

11 September 2017

2

1 reference

11 September 2017

224-243

1 reference

Transurethral prostatectomy: practice aspects of the dominant operation in American urology

11 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

Prazosin in the Treatment of Prostatic Obstruction A Placebo-controlled Study

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

A Placebo-controlled Double-blind Study of the Effect of Phenoxybenzamine in Benign Prostatic Obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

The efficacy and safety of terazosin for the treatment of symptomatic BPH

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

A Randomized, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Terazosin in the Treatment of Benign Prostatic Hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

Implementation of group sequential logrank tests in a maximum duration trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

A brief male sexual function inventory for urology

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

Properties of the urn randomization in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

Recruitment for a clinical trial of drug treatment for benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

An empirical evaluation of the placebo run-in

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

Statistical considerations in the intent-to-treat principle

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

Random-effects models for longitudinal data

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

Unbalanced repeated-measures models with structured covariance matrices.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

Two-Sample Asymptotically Distribution-Free Tests for Incomplete Multivariate Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

Estimators and tests in the analysis of multiple nonindependent 2 x 2 tables with partially missing observations

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

Some large-sample distribution-free estimators and tests for multivariate partially incomplete data from two populations.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

An aid to data monitoring in long-term clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

The B-Value: A Tool for Monitoring Data

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

A flexible stochastic curtailing procedure for the log-rank test.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

Longitudinal changes in peak urinary flow rates in a community based cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2802%2900263-5

7 January 2021

Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia

5

1 reference

https://api.crossref.org/works/10.1016/S0197-2456(02)00263-5

Scandinavian Clinical Study of Finasteride in the Treatment of Benign Prostatic Hyperplasia

23 December 2023

14

1 reference

https://api.crossref.org/works/10.1016/S0197-2456(02)00263-5

Regression Models for Ordinal Data

23 December 2023

42

1 reference

https://api.crossref.org/works/10.1016/S0197-2456(02)00263-5

Discrete sequential boundaries for clinical trials

23 December 2023

49

1 reference

https://api.crossref.org/works/10.1016/S0197-2456(02)00263-5

23 December 2023

Identifiers

1 reference

11 September 2017

1 reference